CA2783858C - Method to use gene expression to determine likelihood of clinical outcome of renal cancer - Google Patents

Method to use gene expression to determine likelihood of clinical outcome of renal cancer Download PDF

Info

Publication number
CA2783858C
CA2783858C CA2783858A CA2783858A CA2783858C CA 2783858 C CA2783858 C CA 2783858C CA 2783858 A CA2783858 A CA 2783858A CA 2783858 A CA2783858 A CA 2783858A CA 2783858 C CA2783858 C CA 2783858C
Authority
CA
Canada
Prior art keywords
gene
lmnb1
patient
expression
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2783858A
Other languages
English (en)
French (fr)
Other versions
CA2783858A1 (en
Inventor
Wayne Cowens
Steven Shak
Audrey Goddard
Dejan Knezevic
Joffre Baker
Michael C. Kiefer
Tara Maddala
Frederick L. Baehner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genomic Health Inc
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Priority to CA3128103A priority Critical patent/CA3128103C/en
Publication of CA2783858A1 publication Critical patent/CA2783858A1/en
Application granted granted Critical
Publication of CA2783858C publication Critical patent/CA2783858C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • G01N33/57525—
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Probability & Statistics with Applications (AREA)
  • Computing Systems (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Pure & Applied Mathematics (AREA)
CA2783858A 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer Active CA2783858C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3128103A CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29403810P 2010-01-11 2010-01-11
US61/294,038 2010-01-11
US34623010P 2010-05-19 2010-05-19
US61/346,230 2010-05-19
PCT/US2011/020596 WO2011085263A2 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3128103A Division CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Publications (2)

Publication Number Publication Date
CA2783858A1 CA2783858A1 (en) 2011-07-14
CA2783858C true CA2783858C (en) 2021-09-14

Family

ID=44258831

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2783858A Active CA2783858C (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3256492A Pending CA3256492A1 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3128103A Active CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA3256492A Pending CA3256492A1 (en) 2010-01-11 2011-01-07 Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CA3128103A Active CA3128103C (en) 2010-01-11 2011-01-07 METHOD FOR USING GENE EXPRESSION TO DETERMINE THE POSSIBILITY OF A CLINICAL OUTCOME OF KIDNEY CANCER

Country Status (12)

Country Link
US (4) US9551034B2 (enExample)
EP (5) EP3178944B1 (enExample)
JP (5) JP6286124B2 (enExample)
AU (1) AU2011203977B2 (enExample)
CA (3) CA2783858C (enExample)
DK (1) DK3178944T3 (enExample)
ES (2) ES2741379T3 (enExample)
IL (6) IL219978A (enExample)
MX (3) MX341866B (enExample)
NZ (4) NZ600268A (enExample)
SG (1) SG181806A1 (enExample)
WO (1) WO2011085263A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3178944T3 (da) 2010-01-11 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer
JP2013532482A (ja) 2010-07-27 2013-08-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現を用いた前立腺癌の予後を定量化する方法
MX341517B (es) 2010-08-13 2016-08-24 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
WO2013016673A2 (en) * 2011-07-27 2013-01-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of dpep1 and tpx2 expression for evaluating treatment or survival time of patients with pancreatic ductal adenocarcinoma
CA2843756A1 (en) * 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof
WO2013063130A1 (en) * 2011-10-24 2013-05-02 Metasignal Therapeutics Inc. Carbonic anhydrase ix-related markers and use thereof
US8725426B2 (en) 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
CA2903878C (en) * 2013-05-30 2020-10-27 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
SG11201602019XA (en) * 2013-09-17 2016-04-28 Agency Science Tech & Res Multigene assay for prognosis of renal cancer
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
JP6638128B2 (ja) * 2014-10-30 2020-01-29 公立大学法人福島県立医科大学 腎がんの悪性度の検査マーカー及び検査方法
US20180044736A1 (en) * 2015-02-03 2018-02-15 Cedars-Sinai Medical Center Biomarker based prognostic model for predicting overall survival in patients with metastatic clear cell kidney cancer
GB201616912D0 (en) 2016-10-05 2016-11-16 University Of East Anglia Classification of cancer
EP3589754B1 (en) 2017-03-01 2023-06-28 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
WO2018161027A1 (en) * 2017-03-03 2018-09-07 Oregon State University Antisense antibacterial compounds and methods
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US11335464B2 (en) * 2018-01-12 2022-05-17 Siemens Medical Solutions Usa, Inc. Integrated precision medicine by combining quantitative imaging techniques with quantitative genomics for improved decision making
WO2020033866A1 (en) * 2018-08-10 2020-02-13 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
WO2020085936A1 (ru) * 2018-10-24 2020-04-30 Общество С Ограниченной Ответственностью "Онкобокс" Тест-классификатор клинического ответа на лечение сорафенибом индивидуальных пациентов с раком почки
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
KR20210132045A (ko) 2019-01-23 2021-11-03 리제너론 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 7(angtl7) 억제제를 사용하는 안구 질환의 트리트먼트
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
MX2023009987A (es) 2021-02-26 2023-09-06 Regeneron Pharma Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7).
CN113025716A (zh) * 2021-03-02 2021-06-25 北京大学第一医院 一种用于人肿瘤分级的基因组合及其用途
CN113817816A (zh) * 2021-10-08 2021-12-21 济南艾迪康医学检验中心有限公司 检测epas1基因突变的引物、试剂盒和方法
WO2023080900A1 (en) * 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
CN118711678B (zh) * 2024-08-22 2025-12-12 暨南大学附属第一医院（广州华侨医院） 一种肾透明细胞肿瘤预测方法、装置、设备及存储介质

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US7135314B1 (en) * 1997-04-17 2006-11-14 Cell Therapeutics, Inc. Human phosphatidic acid phosphatase
JP2003519491A (ja) * 2000-01-13 2003-06-24 ジェネンテック・インコーポレーテッド 新規なｓｔｒａ６ポリペプチド
DE10126344A1 (de) * 2000-07-14 2002-01-24 Max Planck Gesellschaft Apoptose-induzierende DNA-Sequenzen
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
WO2002074237A2 (en) * 2001-03-19 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
CA2442820A1 (en) * 2001-03-29 2002-10-10 Van Andel Institute Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
JP2005500832A (ja) * 2001-06-18 2005-01-13 ロゼッタ・インファーマティクス・インコーポレーテッド 乳癌患者の診断および予後
US7470509B2 (en) * 2002-02-08 2008-12-30 Millennium Pharmaceuticals, Inc. Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
EP2241636A1 (en) 2002-03-13 2010-10-20 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20060183120A1 (en) * 2002-10-04 2006-08-17 Teh Bin T Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
JP2006514554A (ja) 2002-11-21 2006-05-11 ワイス 腎細胞癌および他の固形腫瘍の診断法
EP1618218A2 (en) * 2003-04-29 2006-01-25 Wyeth Methods for prognosis and treatment of solid tumors
ES2787475T3 (es) 2003-06-24 2020-10-16 Genomic Health Inc Predicción de probabilidad de recurrencia del cáncer
EP1644522A2 (en) 2003-07-02 2006-04-12 Novartis AG Genes regulated in ovarian cancer as prognostic and therapeutic targets
US20050002904A1 (en) * 2003-07-03 2005-01-06 Wary Kishore K. Uses of vascular endothelial growth factor and type I collagen inducible protein (VCIP)
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
WO2005024603A2 (en) 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
JP2005211023A (ja) * 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) * 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
US7871769B2 (en) 2004-04-09 2011-01-18 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
WO2005117943A2 (en) * 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
WO2006066071A2 (en) * 2004-12-17 2006-06-22 Mayo Foundation For Medical Education And Research Prognosis of renal cell carcinoma
CA2596469A1 (en) 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
WO2006089185A2 (en) * 2005-02-18 2006-08-24 Wyeth Pharmacogenomic markers for prognosis of solid tumors
WO2006124022A1 (en) 2005-05-13 2006-11-23 Vanandel Research Institute Microarray gene expression profiling in subtypes of clear cell renal cell carcinoma
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
US20070037186A1 (en) * 2005-05-20 2007-02-15 Yuqiu Jiang Thyroid fine needle aspiration molecular assay
CA2611728A1 (en) * 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101228134A (zh) * 2005-06-15 2008-07-23 辉瑞有限公司 用作杀寄生虫剂的取代芳基吡唑
WO2007026896A1 (ja) 2005-09-02 2007-03-08 Toray Industries, Inc. 腎ガン診断、腎ガン患者予後予測のための組成物および方法
CN101292046B (zh) 2005-09-14 2013-03-13 人类遗传标记控股有限公司 健康状态的测定法
EP2332984A3 (en) * 2005-09-30 2011-10-12 Universiteit Maastricht Tumor angiogenesis associated genes and a method for their identification
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8445198B2 (en) * 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
KR20080087822A (ko) 2005-12-16 2008-10-01 제넨테크, 인크. 신경아교종을 진단하고, 예측하고, 치료하는 방법
US20080242606A1 (en) * 2006-06-06 2008-10-02 Zhong Jiang Use of IMP3 as a Prognostic Marker for Cancer
CA2660275A1 (en) * 2006-08-10 2008-02-21 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2008021115A2 (en) 2006-08-14 2008-02-21 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US9034574B2 (en) 2006-12-27 2015-05-19 The Johns Hopkins University Agents for reversing epigenetic silencing of genes
US20080286273A1 (en) 2007-05-02 2008-11-20 Siemens Medical Solutions Usa, Inc. Knowledge-Based Proliferation Signatures and Methods of Use
EP1990417A1 (en) 2007-05-11 2008-11-12 Universität Bayreuth Archaeal plasmid vector system
WO2009105640A1 (en) 2008-02-22 2009-08-27 Virginia Commonwealth University Signatures associated with rejection or recurrence of cancer
CA3153682A1 (en) 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics
WO2010149640A2 (en) * 2009-06-26 2010-12-29 Noviogendix Research B.V. Molecular markers in kidney cancer
EP3739060A1 (en) 2009-11-23 2020-11-18 Genomic Health, Inc. Methods to predict clinical outcome of cancer
DK3178944T3 (da) 2010-01-11 2019-08-12 Genomic Health Inc Fremgangsmåde til anvendelse af genekspression til bestemmelse af sandsynligheden for et klinisk resultat for nyrecancer
KR20140072014A (ko) 2011-06-16 2014-06-12 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CA2843756A1 (en) 2011-08-22 2013-02-28 Somalogic, Inc. Renal cell carcinoma biomarkers and uses thereof

Also Published As

Publication number Publication date
JP2013516195A (ja) 2013-05-13
NZ617003A (en) 2015-04-24
MX375138B (es) 2025-03-06
IL280689A (en) 2021-03-25
MX2012007882A (es) 2012-08-03
JP2019162150A (ja) 2019-09-26
CA3128103A1 (en) 2011-07-14
EP3178944A2 (en) 2017-06-14
EP3178944B1 (en) 2019-05-15
JP6546214B2 (ja) 2019-07-17
DK3178944T3 (da) 2019-08-12
EP3029155A2 (en) 2016-06-08
CA3256492A1 (en) 2025-11-29
JP6286124B2 (ja) 2018-02-28
NZ600268A (en) 2014-08-29
EP2524055A2 (en) 2012-11-21
AU2011203977A1 (en) 2012-06-21
EP2524055A4 (en) 2013-06-05
IL262100B (en) 2019-11-28
WO2011085263A3 (en) 2012-01-12
SG181806A1 (en) 2012-07-30
IL251635A0 (en) 2017-06-29
IL270151B (en) 2021-03-25
US11776664B2 (en) 2023-10-03
EP3831964A3 (en) 2021-10-20
US20210166790A1 (en) 2021-06-03
IL251635B (en) 2018-04-30
CA2783858A1 (en) 2011-07-14
MX341866B (es) 2016-09-06
EP3178944A3 (en) 2017-09-13
IL219978A (en) 2017-04-30
US12412642B2 (en) 2025-09-09
US10892038B2 (en) 2021-01-12
JP7385630B2 (ja) 2023-11-22
EP3831964B1 (en) 2025-04-16
IL262100A (en) 2018-11-29
IL219978A0 (en) 2012-07-31
IL280689B (en) 2022-01-01
MX2020009704A (es) 2020-10-07
EP3561078A1 (en) 2019-10-30
NZ719474A (en) 2018-07-27
ES3027507T3 (en) 2025-06-16
JP2017148059A (ja) 2017-08-31
IL256335B (en) 2018-12-31
US20220051755A9 (en) 2022-02-17
AU2011203977B2 (en) 2015-02-05
CA3128103C (en) 2025-11-18
US20110171633A1 (en) 2011-07-14
EP3029155A3 (en) 2016-08-31
US20170121780A1 (en) 2017-05-04
JP2016174600A (ja) 2016-10-06
NZ705645A (en) 2016-05-27
JP7307602B2 (ja) 2023-07-12
US9551034B2 (en) 2017-01-24
US20240096451A1 (en) 2024-03-21
JP2021177761A (ja) 2021-11-18
EP3831964A2 (en) 2021-06-09
WO2011085263A2 (en) 2011-07-14
ES2741379T3 (es) 2020-02-10

Similar Documents

Publication Publication Date Title
US12412642B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
US20220396842A1 (en) Method for using gene expression to determine prognosis of prostate cancer
US20110123990A1 (en) Methods To Predict Clinical Outcome Of Cancer
AU2015227398B2 (en) Method for using gene expression to determine prognosis of prostate cancer
AU2019268079B2 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40052322B (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40052322A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK40016195A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1263320A1 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1263320B (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
HK1235085A1 (en) Method for using gene expression to determine prognosis of prostate cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151201